Subject category:
Strategy and General Management
Published by:
Babson College
Version: 14 March 2002
Length: 16 pages
Data source: Published sources
Share a link:
https://casecent.re/p/21442
Write a review
|
No reviews for this item
This product has not been used yet
Abstract
This is the fifth of an eight-case series (301-146-1 to 301-149-1 and 302-037-1 to 302-040-1). This case describes UK-based Glaxo Wellcome. During the period 1998-1999, the company focused on respiratory, anti-viral, and central nervous system research. Other areas of research included cardiovascular, oncology, critical care, and metabolic diseases such as diabetes. The case offers a summary of activity in these key areas. Revenue and balance sheet information is also provided. One in a series of eight cases drawn from public information sources. May be used alone or with others in the series Global Biotechnology Winners. Suitable for graduate MBA and executive level courses in strategy, corporate strategy, and strategy relating to biotechnology and pharmaceuticals.
About
Abstract
This is the fifth of an eight-case series (301-146-1 to 301-149-1 and 302-037-1 to 302-040-1). This case describes UK-based Glaxo Wellcome. During the period 1998-1999, the company focused on respiratory, anti-viral, and central nervous system research. Other areas of research included cardiovascular, oncology, critical care, and metabolic diseases such as diabetes. The case offers a summary of activity in these key areas. Revenue and balance sheet information is also provided. One in a series of eight cases drawn from public information sources. May be used alone or with others in the series Global Biotechnology Winners. Suitable for graduate MBA and executive level courses in strategy, corporate strategy, and strategy relating to biotechnology and pharmaceuticals.